StockData
ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc (ANIP) stock

ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$69.99−0.90 (-1.27%)

Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –

ANI Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

ANI Pharmaceuticals's total debt was $301.48M at Jun 30, 2026. For fiscal 2025 it was $309.11M, down 2.9% from the year before. The highest annual figure on record is $318.28M in fiscal 2024.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$309.11M-2.9%
FY2024Dec 31, 2024$318.28M+11.4%
FY2023Dec 31, 2023$285.67M-0.3%
FY2022Dec 31, 2022$286.52M-0.3%
FY2021Dec 31, 2021$287.37M+54.8%
FY2020Dec 31, 2020$185.69M-0.0%
FY2019Dec 31, 2019$185.75M+163.3%
FY2018Dec 31, 2018$70.55M-3.7%
FY2017Dec 31, 2017$73.30M–
FY2016Dec 31, 2016$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$301.48M-4.2%
Q1 FY2026Mar 31, 2026$305.29M-3.5%
Q4 FY2025Dec 31, 2025$309.11M-2.9%
Q3 FY2025Sep 30, 2025$312.92M-2.2%
Q2 FY2025Jun 30, 2025$314.70M+10.3%
Q1 FY2025Mar 31, 2025$316.49M+10.9%
Q4 FY2024Dec 31, 2024$318.28M+11.4%
Q3 FY2024Sep 30, 2024$320.07M+12.0%
Q2 FY2024Jun 30, 2024$285.24M-0.3%
Q1 FY2024Mar 31, 2024$285.46M-0.3%
Q4 FY2023Dec 31, 2023$285.67M-0.3%
Q3 FY2023Sep 30, 2023$285.88M-0.3%
Q2 FY2023Jun 30, 2023$286.09M-0.3%
Q1 FY2023Mar 31, 2023$286.31M-0.3%
Q4 FY2022Dec 31, 2022$286.52M-0.3%
Q3 FY2022Sep 30, 2022$286.73M+42.0%
Q2 FY2022Jun 30, 2022$286.95M+40.2%
Q1 FY2022Mar 31, 2022$287.16M+56.6%
Q4 FY2021Dec 31, 2021$287.37M+54.8%
Q3 FY2021Sep 30, 2021$201.99M+7.5%
Q2 FY2021Jun 30, 2021$204.71M+7.6%
Q1 FY2021Mar 31, 2021$183.42M-8.3%
Q4 FY2020Dec 31, 2020$185.69M-0.0%
Q3 FY2020Sep 30, 2020$187.95M+172.3%
Q2 FY2020Jun 30, 2020$190.21M+172.4%
Q1 FY2020Mar 31, 2020$199.97M+186.7%
Q4 FY2019Dec 31, 2019$185.75M+163.3%
Q3 FY2019Sep 30, 2019$69.03M-3.7%
Q2 FY2019Jun 30, 2019$69.84M-3.6%
Q1 FY2019Mar 31, 2019$69.74M-3.6%
Q4 FY2018Dec 31, 2018$70.55M-3.7%
Q3 FY2018Sep 30, 2018$71.65M–
Q2 FY2018Jun 30, 2018$72.48M–
Q1 FY2018Mar 31, 2018$72.37M–
Q4 FY2017Dec 31, 2017$73.30M–
Q4 FY2016Dec 31, 2016$0–

More ANI Pharmaceuticals figures

See a number that looks wrong?